publicli
fund
repositori
covid
databas
right
unrestrict
research
reus
analys
form
mean
acknowledg
origin
sourc
permiss
grant
free
elsevi
long
resourc
centr
remain
activ
microbiolog
respiratori
system
infect
http
dx
sever
acut
respiratori
syndrom
sar
coronaviru
positivestrand
rna
viru
kb
length
approxim
open
read
frame
identifi
human
pathogen
first
time
part
intens
investig
caus
seri
fatal
pneumonia
case
start
hong
kong
rapidli
spread
differ
countri
outbreak
eventu
brought
control
quarantin
measur
peopl
worldwid
infect
confirm
death
translat
overal
case
fatal
rate
mortal
rate
approach
elderli
like
get
seriou
complic
die
sar
viru
infect
individu
year
age
chronic
ill
diabet
hepat
sar
viru
spread
aerosol
form
respiratori
droplet
close
person
contact
absorb
mucou
membran
typic
incub
period
initi
infect
develop
symptom
day
symptom
includ
high
fever
dri
cough
short
breath
headach
muscl
ach
sore
throat
fatigu
diarrhea
lung
histolog
fatal
case
reveal
mark
diffus
alveolar
damag
inflammatori
cell
infiltr
bronchial
epitheli
denud
loss
cilia
squamou
metaplasia
death
result
respiratori
heart
andor
liver
failur
infect
individu
recov
coronaviru
infect
may
becom
suscept
reinfect
due
rapidli
wane
immun
fact
wane
immun
may
risk
even
sever
diseas
upon
coronaviru
reinfect
sar
homolog
reinfect
studi
show
although
immun
anim
clear
lung
viru
much
faster
naiv
anim
incid
sever
lung
inflamm
reduc
suggest
ill
sever
dictat
sar
viral
load
also
influenc
host
factor
given
possibl
futur
human
outbreak
develop
safe
effect
coronaviru
vaccin
platform
would
benefici
particular
lesson
learn
develop
sar
vaccin
may
also
applic
coronaviru
infect
recent
emerg
middl
east
respiratori
syndrom
mer
coronaviru
initi
attempt
produc
sar
vaccin
candid
base
tradit
method
sar
viru
grown
cell
cultur
biosafeti
level
bsl
condit
inactiv
formaldehyd
betapropriolacton
ultraviolet
irradi
combin
initi
inactiv
whole
viru
vaccin
provid
modest
protect
anim
model
induc
low
titer
neutral
antibodi
earlier
lung
viru
clearanc
complet
prevent
infect
one
inactiv
vaccin
administ
small
number
human
subject
phase
clinic
trial
shown
abl
induc
neutral
antibodi
although
immedi
safeti
issu
identifi
subject
expos
sar
viru
henc
risk
vaccin
exacerb
lung
immunepatholog
vaccin
remain
unknown
note
anim
immun
similar
inactiv
vaccin
develop
sever
lung
eosinophil
immunopatholog
challeng
sar
viru
lung
patholog
exacerb
sar
vaccin
formul
alum
adjuv
attempt
increas
immunogen
despit
inactiv
vaccin
combin
alum
adjuv
abl
reduc
viru
replic
young
anim
fail
reduc
viru
replic
older
anim
use
associ
sever
lung
eosinophil
patholog
postchalleng
find
particularli
concern
elderli
major
target
popul
sar
vaccin
risk
complic
mortal
anim
data
translat
human
suggest
inactiv
vaccin
might
fail
protect
elderli
may
even
increas
risk
seriou
ill
expos
sar
viru
problem
lung
eosinophil
patholog
also
seen
mice
immun
venezuelan
equin
enceph
viru
replicon
particl
express
sar
nucleocapsid
protein
similarli
mice
immun
vaccinia
viru
encod
sar
nucleocapsid
protein
develop
sever
pneumonia
character
increas
cytokin
reduc
tgfbeta
thicken
alveolar
epithelium
lung
infiltr
eosinophil
lymphocyt
neutrophil
henc
given
problem
poor
immunogen
difficulti
manufactur
poor
efficaci
elderli
risk
exacerb
diseas
due
eosinophil
lung
immunopatholog
inactiv
whole
viru
formul
poor
candid
safe
effect
sar
vaccin
major
advanc
vaccin
develop
identif
sar
viru
spike
protein
mediat
cell
entri
via
abil
bind
angiotensinconvert
enzym
therebi
trigger
viru
endocytosi
target
cell
human
monoclon
antibodi
bind
protein
ntermin
domain
shown
abl
block
infect
therebi
identifi
protein
major
target
sar
viru
neutral
antibodi
consist
monkey
could
protect
sar
infect
intranas
immun
proteinencod
live
parainfluenza
vector
protein
also
shown
target
cell
respons
suggest
may
also
import
sar
protect
recombin
protein
vaccin
manufactur
use
insect
cell
express
system
found
consider
less
immunogen
inactiv
whole
viru
vaccin
requir
time
antigen
achiev
level
immunogen
attempt
improv
immunogen
protein
vaccin
sarsassoci
eosinophil
lung
immunopatholog
formul
alum
adjuv
result
sever
lung
eosinophil
immunopatholog
respons
sar
viru
infect
mark
anoth
potenti
unsaf
approach
confirm
problem
lung
eosinophil
immunopatholog
confin
inactiv
nucleocapsid
protein
vaccin
gener
problem
vaccin
made
sar
viru
antigen
mechanist
basi
lung
eosinophil
immunopatholog
question
academ
interest
sarsassoci
lung
immunopatholog
bear
strike
resembl
lung
eosinophil
patholog
previous
seen
alumadjuv
formalininactiv
respiratori
syncyti
viru
rsv
vaccin
clinic
trial
vaccin
caus
increas
mortal
immun
children
becam
infect
rsv
henc
sar
vaccin
induc
lung
eosinophil
immunopatholog
could
equal
unsaf
human
subject
lung
eosinophil
immunopatholog
aris
naiv
mice
pretreat
anti
protein
antibodi
challeng
suggest
due
antibodydepend
enhanc
mechan
lung
immunopatholog
might
instead
due
aberr
host
immun
respons
sar
viru
exacerb
vaccin
prime
abil
inactiv
recombin
vaccin
induc
eosinophil
immunopatholog
dramat
exacerb
formul
alum
adjuv
known
adjuv
impli
problem
might
vaccin
prime
excess
andor
fail
prime
suffici
respons
sar
viru
mediat
broad
rang
immun
modulatori
effect
might
expect
lead
strong
immun
bia
protein
bind
lung
surfact
protein
collectin
found
lung
activ
macrophag
dendrit
cell
dc
autopsi
lung
sampl
patient
die
sar
infect
reveal
regul
type
interferon
chemokin
involv
cell
recruit
inhibit
pathway
convers
sar
viru
enhanc
product
inflammatori
cytokin
inhibit
abil
dc
prime
cell
gurich
ssrna
sar
viru
activ
mice
therebi
induc
high
level
proinflammatori
cytokin
includ
lead
lethal
acut
lung
injuri
thu
sar
viru
capac
exacerb
lung
inflamm
time
inhibit
antivir
interferon
respons
sar
viru
use
multipl
mechan
inhibit
host
type
interferon
respons
open
read
frame
orf
orf
nucleocapsid
protein
play
major
role
nucleocapsid
protein
inhibit
synthesi
interferon
orf
orf
protein
inhibit
interferon
synthesi
signal
addit
orf
protein
inhibit
nuclear
transloc
import
protect
demonstr
knockout
mice
unabl
clear
sar
viru
infect
result
increas
viru
lethal
furthermor
mice
infect
sar
viru
evid
cell
macrophag
dysregul
increas
altern
activ
macrophag
immun
respons
essenti
develop
altern
activ
macrophag
import
altern
activ
macrophag
sar
patholog
abl
demonstr
use
doubleknockout
mice
exhibit
reduc
lung
diseas
respons
sar
viru
challeng
host
side
cell
respons
viru
clearanc
adopt
transfer
immun
splenocyt
sarsspecif
cell
reduc
lung
viru
titer
enhanc
surviv
import
immun
viral
control
may
help
explain
mani
mechan
sar
viru
develop
subvert
respons
suppress
respons
sar
viru
may
therebi
impart
unbalanc
bia
antivir
lung
immun
respons
could
amplifi
exagger
preexist
bia
alreadi
impart
immun
bias
sar
vaccin
therebi
provid
plausibl
explan
vaccineexacerb
lung
eosinophil
patholog
observ
recipi
alumadjuv
unadjuv
inactiv
whole
viru
recombin
protein
vaccin
support
data
ferret
sar
viru
reinfect
model
reinfect
anim
ferret
previous
immun
alumadjuv
inactiv
vaccin
candid
fail
mount
effect
type
interferon
respons
mice
sarsassoci
lung
patholog
shown
prevent
pretreat
alveolar
macrophag
poli
c
agonist
may
reflect
abil
prime
strong
type
interferon
respons
henc
aberr
host
immun
respons
caus
sarsassoci
lung
immunopatholog
complex
role
play
altern
activ
macrophag
neutrophil
nfkb
activ
lack
type
interferon
respons
excess
tnf
product
due
inflammasom
activ
sar
envelop
proteinencod
ion
channel
elderli
human
subject
infect
sar
viru
experienc
extrem
high
mortal
rate
approach
sarsinfect
age
macaqu
similarli
develop
sever
patholog
young
adult
anim
even
though
viral
replic
level
similar
suggest
increas
sar
mortal
elderli
may
reflect
much
aberr
host
respons
toxic
effect
viru
keep
age
macaqu
show
greater
nfkb
activ
respons
sar
infect
associ
increas
inflammatori
gene
express
lower
express
type
interferon
treatment
age
anim
type
interferon
reduc
express
inflammatori
gene
reduc
lung
patholog
despit
chang
lung
viru
level
shown
age
mice
exhibit
increas
lung
prostaglandin
respons
lung
infect
correl
impair
dc
migrat
lower
cell
respons
sever
clinic
diseas
age
anim
could
attenu
block
prostaglandin
smallmolecul
antagonist
thu
multipl
factor
like
contribut
increas
mortal
elderli
subject
suffer
sar
infect
includ
intrins
dc
defect
increas
product
dcinhibitori
factor
prostaglandin
predisposit
increas
inflammatori
respons
reduc
immun
respons
ongo
challeng
develop
sar
viru
vaccin
strategi
abl
overcom
obstacl
therebi
safe
effect
elderli
critic
need
identifi
suitabl
sar
vaccin
run
risk
exacerb
coronavirusassoci
lung
immunopatholog
polysaccharid
adjuv
base
microcrystallin
particl
poli
fructofuranosyl
delta
inulin
shown
enhanc
vaccin
immun
wide
varieti
pathogen
includ
influenza
japanes
enceph
west
nile
viru
hepat
b
enhanc
humor
cellular
immun
induc
balanc
respons
also
shown
safe
nonreactogen
human
vaccin
trial
combin
either
recombin
protein
inactiv
sar
adjuv
alon
combin
agonist
enhanc
neutral
antibodi
cellular
immun
respons
reduc
lung
viral
load
complet
protect
sar
lethal
notabl
anim
immun
adjuv
formul
minim
lung
eosinophil
patholog
postchalleng
stark
contrast
sever
immunopatholog
observ
anim
immun
antigen
alon
combin
alum
adjuv
fig
therebi
highlight
critic
import
adjuv
select
sar
vaccin
develop
protect
lung
immunopatholog
correl
strong
memori
respons
anim
mice
immun
variou
sar
antigen
formul
challeng
sar
viru
lung
harvest
day
postchalleng
stain
h
e
plu
specif
eosinophil
stain
brown
sar
challeng
mice
receiv
vehicl
control
mark
lung
inflamm
minim
eosinophil
contrast
mice
immun
either
alumadjuv
protein
b
unadjuv
inactiv
whole
viru
c
exhibit
florid
lung
eosinophil
infiltr
howev
minim
eosinophil
seen
mice
immun
inactiv
whole
viru
vaccin
formul
adjuv
tlr
agonist
includ
lipopolysaccharid
poli
u
poli
c
formul
inactiv
sar
viru
similarli
shown
help
prevent
lung
immunopatholog
success
strategi
common
prime
respons
suggest
key
avoid
lung
eosinophil
immunopatholog
protect
sar
viru
involv
coordin
action
memori
cell
neutral
antibodi
vaccin
fail
induc
immun
sar
viru
run
risk
exacerb
lung
diseas
henc
key
success
sar
vaccin
inclus
adjuv
abl
induc
robust
cellular
immun
togeth
longliv
neutral
antibodi
import
question
remain
best
protect
elderli
subject
vulner
popul
lethal
human
coronavirus
anoth
import
issu
best
provid
protect
heterolog
sar
viru
strain
unfortun
passag
time
sinc
sar
epidem
fund
sar
research
dri
question
may
never
answer
sar
epidem
halt
quarantin
measur
ongo
need
safe
effect
vaccin
platform
could
use
event
futur
human
coronaviru
threat
notabl
mer
coronaviru
emerg
becom
major
human
threat
unlik
sar
mer
halt
quarantin
procedur
creat
urgent
need
safe
effect
mer
vaccin
yet
known
whether
mer
vaccin
suffer
problem
sar
vaccin
low
immunogen
lung
eosinophil
immunopatholog
seem
like
henc
similar
strategi
describ
requir
make
mer
vaccin
safe
effect
mer
almost
certainli
last
new
coronaviru
caus
human
diseas
identifi
need
ongo
research
uniqu
hostpathogen
interact
contribut
coronaviru
patholog
infect
outcom
develop
effect
coronaviru
vaccin
platform
